Personalis, Inc. (NASDAQ: PSNL) has unveiled breakthrough clinical data showing its NeXT Personal ctDNA blood test can ...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced the presentation of new clinical results from the PREDICT DNA and SCANDARE studies highlighting the ...

Gilead Sciences' TROP2-targeting drug Trodelvy is already used as a third-line treatment for PD-L1-positive triple-negative ...

CHICAGO -- Combining pembrolizumab (Keytruda) with sacituzumab govitecan (SG, Trodelvy) instead of chemotherapy as first-line ...

Stratification factors comprised region (US/Canada/Western Europe vs the rest of the world), previous exposure to PD-(L)1 inhibition (yes versus no), and curative treatment-free interval (de novo TNBC ...

Stratification factors comprised region (US/Canada/Western Europe vs the rest of the world), previous exposure to PD-(L)1 inhibition (yes vs no), and curative treatment-free interval (de novo TNBC vs ...

Stratification factors comprised region (US/Canada/Western Europe vs the rest of the world), previous exposure to PD-(L)1 inhibition (yes vs no), and curative treatment-free interval (de novo TNBC vs ...

Study presented at ESMO Breast 2025 finds specific gut bacteria and microbial enzymes may be linked to breast cancer ...

The chances of recurrence are particularly high during the first few years ... This means that 65 in every 100 patients of TNBC (that has spread) are alive after five years. For perspective, other ...

From antibody-drug conjugates to PARP inhibitors, innovative treatments are offering new hope for patients with ...

Thanks to advances in medical care, the chances of recurrence from triple-negative breast cancer have gone down significantly. However, statistics still show that Black women had an overall 4% higher ...